Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Telix Pharmaceuticals (Innovations) Pty Limited
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
The New York Proton Center
Novelwise Pharmaceutical Corporation
Iambic Therapeutics, Inc
NaviFUS Corporation
Waikato Hospital
Parabilis Medicines, Inc.
NaviFUS Corporation
NaviFUS Corporation
Stemline Therapeutics, Inc.
Actuate Therapeutics Inc.
University Hospital, Caen
Ottawa Hospital Research Institute
Pfizer
Tianjin Medical University Cancer Institute and Hospital
Vanderbilt-Ingram Cancer Center
Eli Lilly and Company
Rigel Pharmaceuticals
RasCal Therapeutics, Inc.
Coherence Neuro Australia Pty Limited
Children's Hospital of Philadelphia
Baptist Health South Florida
Baptist Health South Florida
GT Medical Technologies, Inc.
Emory University
Assistance Publique - Hôpitaux de Paris
Cancer Research UK
Memorial Sloan Kettering Cancer Center
Essen Biotech
Essen Biotech
Pediatric Brain Tumor Consortium
Medical University of South Carolina
Children's Hospital Los Angeles
Australian & New Zealand Children's Haematology/Oncology Group
University of Maryland, Baltimore
EMD Serono
GlaxoSmithKline
Telix Pharmaceuticals (Innovations) Pty Limited
Eli Lilly and Company
Var2 Pharmaceuticals
Reveal Pharmaceuticals Inc.
Institut du Cancer de Montpellier - Val d'Aurelle
Odense University Hospital
Degron Therapeutics Co.